Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03861403
Title A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Leap Therapeutics, Inc.

triple-receptor negative breast cancer

breast carcinoma

ovary epithelial cancer

Advanced Solid Tumor

fallopian tube cancer

prostate adenocarcinoma

peritoneum cancer


Avelumab + Cyclophosphamide + TRX518

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.